AzTrials
AzTrials

Fibrocystic Breast DiseasePhase 4NCT05717894

Possibilities of Phytomedicine in Monotherapy of Benign Breast Diseases

A Phase 4 study testing Vitex Agnus Castus Extract in people with Fibrocystic Breast Disease, run by Nazgul Omarbayeva at 1 site in Kazakhstan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to evaluate the effectiveness of the use of the drug, containing Vitex agnus castus extract (VAC), in patients with fibrocystic breast disease . One hundred fifty women over 40 years old were randomized into patient (n=78) and control (n=72) groups. Read more about this study

Who is it for?
Ages 18 to 80 years, women only
Conditions the study is for
Fibrocystic Breast Disease
What is being tested?
Vitex Agnus Castus Extract
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 siteKazakhstan
Study dates
11 Jan 2020to 10 Jun 2022
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 to 80 years old
  • Must be able to visit the investigators at the appointesssd time.

Who cannot join

  • refused to sign informed consent
  • pregnant and breastfeeding
  • has severe chronic comorbid diseases (cancer, diabetes mellitus, systemic blood diseases, neuralgia, suffering from mental illness or legally incompetent, e.g.)
  • participated in another clinical trial

Trial locations and contacts

1 site in 1 country.

Kazakhstan1 site
  • Kazakh Institute of Oncology and Radiology

    Almaty, Almaty Region

Other trials in Kazakhstan

About this study

Official title: Randomized, Post-marketing, Open-label, Observational, Non-interventional, Comparative, Controlled, Monocenter Study of the Efficacy and Safety of Mastodinone in Patients With Fibrocystic Breast Disease

The aim of this study is to evaluate the effectiveness of the use of the drug, containing Vitex agnus castus extract (VAC), in patients with fibrocystic breast disease . One hundred fifty women over 40 years old were randomized into patient (n=78) and control (n=72) groups. The groups were similar regarding age, nulliparity, menopause and abortion status, family history of breast cancer, alcohol consumption, and smoking. The patient group received two pills containing 200mg of VAC daily for six months, and all participants were evaluated by using a Visual Analogue Scale and ultrasound examination at baseline, 12th and 24th weeks.

Read the detailed description

One hundred fifty patients presented at the Kazakh Institute of Oncology and Radiology diagnosed with FBD between January 2020, and May 2022 were prospectively enrolled in this study. The diagnosis was established based on complaints, palpation, and ultrasound findings. The patients over 40 years were also routinely screened by mammography to avoid breast cancer before including the study. Then, all patients were randomized one-to-one into either the control group (n=72) or the treatment (primary) group (n=78) according to the order of admission to the hospital. The envelope method was used so that the doctor and radiologist who performed the examination and ultrasound of the patients did not know which arm the patients were in.

Persistent pain was identified as a pain that lasts more than 3 months despite medication or treatment . The treatment group received two pills containing 200mg of VAC daily for six months, while the investigators followed the control group during the same period. Treatment responses were assessed using some subjective like the intensity of breast pain (from no pain=10 to unbearable pain=10), breast tenderness, and objective measures like palpable lumps and ultrasonographic examination performed at baseline, 12th and 24th weeks after the treatment by the same equipment and investigator. For the evaluation of breast pain at baseline and follow-up, a visual analogue scale marked from "no pain" to "unbearable pain" was used. Patients were asked to choose pictures of faces ranging from smiling to pain-contorted, conveying their perception of pain severity . Pain intensity was assessed using a visual analogue scale (VAS) in scores. The state of breast tissue was evaluated according to ultrasound findings; progression (increase in size and/or the number of cysts or fibrosis), stabilization (no clinically significant changes), and regression (partial or complete clinical response).

All participants read and signed written informed consent. The study was conducted at the Kazakh Institute of Oncology and Radiology based on a protocol proposed by the research team and approved by the Local Ethics committee according to principles of the World Medical Association (WMA) the Declaration of Helsinki 08/19 from 30th of October 2019.

Statistical analysis To compare the subgroups in terms of numerical variables, the normality was assessed by the Kolmogorov-Smirnov normality test, and the homogeneity of group variances was assessed by the Levene test. Mann-Whitney U test was used to determine the difference in the groups with median (minimum-maximum values) as descriptive statistics due to the skewed nature of those variables. Frequencies and percentages were presented to describe the categorical variables. The association between the groups and categorical variables was assessed with univariate analysis by the Pearson Chi-square test or fisher exact test, and the Bonferroni method was used to compare subgroups; if there was no difference between the groups, it was shown with the same letter, and if there was a difference, it was shown with a different letter. The IBM SPSS Statistics (version 25.0 for Windows, Chicago, IL, USA) was used, and p<0.05 was considered significant for all statistical analyses.

Being tested
Vitex Agnus Castus Extract
Medical subject headings
Fibrocystic Breast Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vitex Agnus Castus ExtractDrug

    Also called Mastodynone

    The patient group received two pills containing 200mg of VAC daily for six months

Study groups in NCT05717894
Study groupRoleWhat they receive
Treatment ( primary )ExperimentalNot described
Receives: Drug: Vitex Agnus Castus Extract
ControlNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual analogue scale

    Commonly used pain measurement scale: the 11-point numeric rating scale, the visual analogue scale (VAS) from no pain to unbearable pain, and the five-point categorical verbal rating scale. VAS scores: from 0 to 10: 0 - no pain; 1-3 - mild pain; 4-6 - moderate pain; 7-9 - severe pain; and 10 - unbearable pain

    Measured: every 3 months up to 6 months

  2. Ultrasound

    Ultrasound was used to assess the size of cysts, lumps, ducts, fibroadenomas

    Measured: every 3 months up to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2023
  2. Study start11 Jan 2020
  3. Primary completion15 May 2022
  4. Study completion10 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
all patients were randomized one-to-one into either the control group (n=72) or the treatment (primary) group (n=78) according to the order of admission to the hospital
Masking
None (open label)
Enrolment
150 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05717894
Sponsor's protocol ID
MastoVit150
Status last verified
Jan 2023
First submitted
19 Jan 2023
Last updated
8 Feb 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Vitex Agnus Castus Extract in people with Fibrocystic Breast Disease, run by Nazgul Omarbayeva at 1 site in Kazakhstan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual analogue scale (time frame: every 3 months up to 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in